Eldad Tzahor, wanted to know exactly how NRG1 and ERBB2
are involved in heart regeneration.
In a combined analysis of immunohistochemical staining of grade 3 endometrioid endometrial carcinomas for MLH1, MSH2, p16, cyclin D1, ERBB2
, WT1, and p53,37% of cases had molecular profiles that resembled endometrioid carcinomas, and the other 63% of cases resembled serous carcinomas at the molecular level (57).
An additional 2% of NSCLC cases harbor mutations in phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA), (22) and unlike ERBB2
, EGFR, and KRAS mutations, which are mutually exclusive in lung cancer, PIK3CA mutations can co-occur in tumors with EGFR mutations.
Further research is needed to confirm ERBB2
's role in cetuximab resistance and to develop strategies for testing ERBB2
inhibitors in clinical trials.
In the study, "ERBB2
(HER2) Mutational Spectrum in Solid Tumors," Caris analyzed the ERBB2
gene in nearly 7,500 breast, colorectal, lung, uterine/cervical, ovarian, bladder and pancreatic cancer patients.
Most histochemistry and immunohistochemistry procedures are based on formalin fixation, and for those laboratories handling breast tissues, formalin is accepted for the ERBB2
(formerly HER2 or HER2/neu) immunohistochemistry procedures.
Additionally, none of the fusion-positive tumors contained alterations in any of the other known oncogenes that drive lung cancer (EGFR , ERBB2
, BRAF or KRAS or rearrangements of EML4 -ALK or ROS1).
They found that cancers over expressing ERBB2
have increased expression of genes that regulate proteins in what turns out to be an important survival mechanism for HER2 cancer cells -- the endoplasmic reticulum associated degradation pathway, or ERAD.
ERBB3 can also activate AR independently of the PI3K/AKT pathway by stabilizing AR protein in complex with ERBB2
(24), and secreted ERBB3 promotes bone metastasis (25).
HER2 fluorescence in situ hybridization (FISH) examination revealed an increased ratio of ERBB2
(HER2) gene when compared with CEP17 (Figure 4, A).
The panel's recommendations support the clinical value of Agendia's BluePrint assay, which, in combination with the company's FDA-cleared MammaPrint recurrence test, can accurately classify all patients as Basal, Luminal-A, Luminal-B, or ERBB2
(HER2) and help determine appropriate treatment.
To date, the ERBB2
amplification is the only GA in advanced gastric cancer associated with a survival benefit in response to targeted therapy.